This Due Diligence Information Document is to solicit information for selection of partner(s) for commercialization of a first-in-class antibiotic – Zoliflodacin Powder for Oral Suspension – the only drug being developed specifically to treat resistant strains of gonorrhea (“Product”).

The partner must have a demonstrably viable plan as well as prior experience in successful commercialization of oral / injectable antibiotic, antiviral & anti-HIV products, preferably for Sexually Transmitted Diseases targeting the community-care settings.

The goal of this due diligence information is to identify a commercial partner (“Distributor”) to market & distribute the Product initially in South Africa & Thailand, the (“Territory”) in alignment with GARDP’s Market Access Plan.

Instructions for Due Diligence Information Document

Due Diligence Information Document

Closing date: November 14th 2023